---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033753"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:51:02.956062+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BriaCell receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Feb 18, 2025

## Summary
- Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.
- Has until Feb 18, 2025 to regain compliance via closing bid price of $1.00+ for 10 consecutive days.
- May qualify for second 180-day cure period if it meets other listing standards and effects a reverse split.
- TSX listing unaffected; common shares continue trading on Nasdaq under BCTX.

## SEC filing metadata
- accession: 0001493152-24-033753
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224033753/0001493152-24-033753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224033753/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033753
- JSON: https://secwatch.observer/filing/0001493152-24-033753.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.